Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.

Pembrolizumab is used to treat various types of cancer, including melanoma, non-small cell lung cancer and head and neck squamous cell cancer.

AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...

Merck (NYSE: MRK) closed Tuesday's session down 0.87% at $128.26, breaking a six-session winning streak. The stock had gained 13.62% over the preceding six trading sessions, outperforming the S&P 500, ...

Sen. Maggie Hassan is pressing pharmaceutical giant Merck over access and cost issues around one of its most popular and best ...

Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an increasingly intertwined human-machine model moves closer to adoption in real-world ...

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda 1 (pembrolizumab), have met their primary endpoints. “We are excited to ...

On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two ...

In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have ...

Two major studies are looking at moving sacituzumab govitecan earlier for metastatic triple-negative breast cancer.

The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or ...

(Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy ® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), ...